<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390052</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00139</org_study_id>
    <secondary_id>NCI-2009-00139</secondary_id>
    <secondary_id>PHI-52</secondary_id>
    <secondary_id>CDR0000507731</secondary_id>
    <secondary_id>PHI-52</secondary_id>
    <secondary_id>7225</secondary_id>
    <secondary_id>U01CA062505</secondary_id>
    <nct_id>NCT00390052</nct_id>
  </id_info>
  <brief_title>3-AP in Treating Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone(3-AP,Triapine) in the Treatment of Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of 3-AP in treating patients&#xD;
      with advanced or metastatic solid tumors. 3-AP may stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety, tolerability, and toxicity of oral 3-AP in patients with advanced&#xD;
      solid tumors.&#xD;
&#xD;
      II. Determine the maximum tolerated dose and recommended phase II dose of this drug in these&#xD;
      patients.&#xD;
&#xD;
      III. Determine the oral bioavailability and pharmacokinetics of this drug. IV. Assess tumoral&#xD;
      expression of genes involved in response and resistance to 3-AP.&#xD;
&#xD;
      V. Observe and record any tumor response in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive a one time dose of 3-AP IV over 2 hours on day -7. Patients then receive&#xD;
      oral 3-AP twice daily on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive&#xD;
      escalating doses of oral 3-AP until the maximum tolerated dose (MTD) is determined. The MTD&#xD;
      is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience&#xD;
      dose-limiting toxicity. Blood samples for pharmacokinetic analysis are collected periodically&#xD;
      over 8 hours after the IV dose of 3-AP and after the first oral dose of 3-AP during course 1.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of oral 3-AP determined by dose-limiting toxicities graded according to the NCI CTCAE version 3.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum pharmacokinetics of oral triapine</measure>
    <time_frame>Baseline, day 4, and day 8</time_frame>
    <description>Summary statistics of the pharmacokinetic parameters will be tabulated using the logarithmic scale where appropriate. The relationship of the AUC to the dose will be assessed by least-square regression analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
    <description>Given IV and orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>3-AP</other_name>
    <other_name>OCX-191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  Must be able to swallow&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
          -  Advanced or metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known active CNS metastases&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Progressive disease during &gt;= 1 prior standard therapy OR disease unlikely to respond&#xD;
             to any currently available therapies&#xD;
&#xD;
          -  Patients with previously treated CNS metastases who have no evidence of new CNS&#xD;
             metastases AND are stable for &gt;= 2 months are eligible&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 10 g/dL (transfusions allowed)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  ALT and AST =&lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2.5 times ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL OR creatinine clearance &gt;= 50 mL/min&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  PT/PTT =&lt; 1.5 times ULN&#xD;
&#xD;
          -  FEV1 &gt;= 1.2 L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 2 weeks prior to and during study&#xD;
             treatment&#xD;
&#xD;
          -  No mental deficits and/or psychiatric history that may preclude study treatment&#xD;
&#xD;
          -  No active heart disease, including any of the following: myocardial infarction within&#xD;
             the past 3 months, symptomatic coronary artery disease or heart block, uncontrolled&#xD;
             congestive heart failure&#xD;
&#xD;
          -  No moderate to severe compromise of pulmonary function&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No active coagulation disorder other than occult blood&#xD;
&#xD;
          -  No known positivity for glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Recovered from prior treatment&#xD;
&#xD;
          -  Prior gemcitabine allowed&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy or any other treatment for this cancer&#xD;
&#xD;
          -  No prior 3-AP&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Yen</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

